Cargando…

Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension

Selection of endpoints for clinical trials in pulmonary arterial hypertension (PAH) is challenging because of the small numbers of patients and the changing expectations of patients, clinicians, and regulators in this evolving therapy area. The most commonly used primary endpoint in PAH trials has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caccamo, Marco, Harrell, Frank E., Hemnes, Anna R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405062/ https://www.ncbi.nlm.nih.gov/pubmed/37554146 http://dx.doi.org/10.1002/pul2.12271

Ejemplares similares

Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
por: Wang, An, et al.
Publicado: (2023)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Identifying “super responders” in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2017)

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
por: Hemnes, Anna R., et al.
Publicado: (2017)

Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension
por: Hemnes, Anna, et al.
Publicado: (2020)

Evidence of pulmonary arterial hypertension in two patients with common variable immunodeficiency
por: Huston, Jessica, et al.
Publicado: (2020)

Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension
por: Brittain, Evan L., et al.
Publicado: (2020)

CD44 and xCT: The Silver Bullet for Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension?
por: Agrawal, Vineet, et al.
Publicado: (2019)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Reduced free-living activity levels in pulmonary arterial hypertension patients
por: Halliday, Stephen J., et al.
Publicado: (2018)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs
por: Phillips, Patrick PJ, et al.
Publicado: (2011)

Clinical trial design and new therapies for pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2019)

An evidence-based knowledgebase of pulmonary arterial hypertension to identify genes and pathways relevant to pathogenesis
por: Zhao, Min, et al.
Publicado: (2014)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)

Approach to a patient with pulmonary hypertension
por: Inampudi, Chakradhari, et al.
Publicado: (2019)

Is more involvement needed in the clinical trial design & endpoints?
por: Vroom, Elizabeth
Publicado: (2012)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
por: Nathan, Steven D., et al.
Publicado: (2022)

Clinical features do not identify risk of progression from isolated postcapillary pulmonary hypertension to combined pre‐ and postcapillary pulmonary hypertension
por: Babu, Gautam, et al.
Publicado: (2023)

Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension
por: Trammell, Aaron W., et al.
Publicado: (2017)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

Hemodynamic Improvement of Pulmonary Arterial Hypertension After Bariatric Surgery: Potential Role for Metabolic Regulation
por: Pugh, Meredith E., et al.
Publicado: (2013)

Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension
por: Lachant, Daniel, et al.
Publicado: (2023)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

An algorithm to identify cases of pulmonary arterial hypertension from the electronic medical record
por: Schuler, Kyle P., et al.
Publicado: (2022)

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms
por: Mathai, Stephen C., et al.
Publicado: (2019)

Proof of concept demonstration of optimal composite MRI endpoints for clinical trials
por: Edland, Steven D., et al.
Publicado: (2016)

Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials
por: Becker, Jan Ulrich, et al.
Publicado: (2022)

Optimal experimental designs for dose–response studies with continuous endpoints
por: Holland-Letz, Tim, et al.
Publicado: (2014)

Analysis and design of randomised clinical trials involving competing risks endpoints
por: Tai, Bee-Choo, et al.
Publicado: (2011)

Advancing clinical trial design in pulmonary hypertension
por: Grieve, Andy P., et al.
Publicado: (2013)

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015)

Beyond the Diagnosis of Group IV Pulmonary Hypertension: Chronic Thromboembolic Pulmonary Hypertension Mimickers
por: Chima, Noor Rehman, et al.
Publicado: (2020)

High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach
por: Shah, Nisha B., et al.
Publicado: (2019)

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
por: Murthy, Sandhya, et al.
Publicado: (2021)

British randomised controlled trial of AV and VV optimization (“BRAVO”) study: rationale, design, and endpoints
por: Whinnett, Zachary I, et al.
Publicado: (2014)

Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial
por: Sharif, Faisal, et al.
Publicado: (2022)

The evolution of survival of pulmonary arterial hypertension over 15 years
por: Hendriks, Paul M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b06l38a73miijb9cj9d4f3lps9